|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
McKenzie S, Mailey B, Artinyan A,
Metchikian M, Shibata S, Kernstine K and Kim J: Improved outcomes
in the management of esophageal cancer with the addition of
surgical resection to chemoradiation therapy. Ann Surg Oncol.
18:551–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mariette C, Taillier G, Van Seuningen I
and Triboulet JP: Factors affecting postoperative course and
survival after en bloc resection for esophageal carcinoma. Ann
Thorac Surg. 78:1177–1183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruol A, Rizzetto C, Castoro C, et al:
Interval between neoadjuvant chemoradiotherapy and surgery for
squamous cell carcinoma of the thoracic esophagus: does delayed
surgery have an impact on outcome? Ann Surg. 252:788–796. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hironaka S, Ohtsu A, Boku N, et al:
Nonrandomized comparison between definitive chemoradiotherapy and
radical surgery in patients with T (2–3) N (any) M (0) squamous
cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys.
57:425–433. 2003.PubMed/NCBI
|
|
6
|
Park BB, Im YH, Hwang IG, et al: Salvage
chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for
previously treated metastatic or recurrent esophageal squamous cell
carcinoma. Invest New Drugs. 26:387–392. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin J, Xu X, Wang F, et al: Second-line
combination chemotherapy with docetaxel and nedaplatin for
Cisplatin-pretreated refractory metastatic/recurrent esophageal
squamous cell carcinoma. J Thorac Oncol. 4:1017–1021. 2009.
View Article : Google Scholar
|
|
8
|
Li Y, Wo JM, Ray MB, Jones W, Su RR, Ellis
S and Martin RC: Cyclooxygenase-2 and epithelial growth factor
receptor up-regulation during progression of Barrett’s esophagus to
adenocarcinoma. World J Gastroenterol. 12:928–934. 2006.PubMed/NCBI
|
|
9
|
Gibault L, Metges JP, Conan-Charlet V, et
al: Diffuse EGFR staining is associated with reduced overall
survival in locally advanced oesophageal squamous cell cancer. Br J
Cancer. 93:107–115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoshino M, Fukui H, Ono Y, et al: Nuclear
expression of phosphorylated EGFR is associated with poor prognosis
of patients with esophageal squamous cell carcinoma. Pathobiology.
74:15–21. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shaheen NJ, Crosby MA, Bozymski EM and
Sandler RS: Is there publication bias in the reporting of cancer
risk in Barrett’s esophagus? Gastroenterology. 119:333–338.
2000.
|
|
12
|
Goldman A, Chen HD, Roesly HB, et al:
Characterization of squamous esophageal cells resistant to bile
acids at acidic pH: implication for Barrett’s esophagus
pathogenesis. Am J Physiol Gastrointest Liver Physiol.
300:G292–G302. 2011.PubMed/NCBI
|
|
13
|
Wang QS, Sabourin CL, Bijur GN, Robertson
FM and Stoner GD: Alterations in transforming growth factor-alpha
and epidermal growth factor receptor expression during rat
esophageal tumorigenesis. Mol Carcinog. 15:144–153. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong L, Debruyne PR, Witek M, et al: Bile
acids initiate lineage-addicted gastroesophageal tumorigenesis by
suppressing the EGF receptor-AKT axis. Clin Transl Sci. 2:286–293.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marx AH, Zielinski M, Kowitz CM, et al:
Homogeneous EGFR amplification defines a subset of aggressive
Barrett’s adenocarcinomas with poor prognosis. Histopathology.
57:418–426. 2010.PubMed/NCBI
|
|
16
|
Yacoub L, Goldman H and Odze RD:
Transforming growth factor-alpha, epidermal growth factor receptor,
and MiB-1 expression in Barrett’s-associated neoplasia: correlation
with prognosis. Mod Pathol. 10:105–112. 1997.PubMed/NCBI
|
|
17
|
Andl CD, Mizushima T, Nakagawa H, et al:
Epidermal growth factor receptor mediates increased cell
proliferation, migration, and aggregation in esophageal
keratinocytes in vitro and in vivo. J Biol Chem. 278:1824–1830.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miller CT, Moy JR, Lin L, et al: Gene
amplification in esophageal adenocarcinomas and Barrett’s with
high-grade dysplasia. Clin Cancer Res. 9:4819–4825. 2003.
|
|
19
|
Rygiel AM, Milano F, Ten Kate FJ, et al:
Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no
dysplasia-dysplasia-adenocarcinoma sequence of Barrett’s esophagus.
Cancer Epidemiol Biomarkers Prev. 17:1380–1385. 2008.PubMed/NCBI
|
|
20
|
Owonikoko T, Rees M, Gabbert HE and Sarbia
M: Intratumoral genetic heterogeneity in Barrett adenocarcinoma. Am
J Clin Pathol. 117:558–566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gebhardt F, Zänker KS and Brandt B:
Modulation of epidermal growth factor receptor gene transcription
by a polymorphic dinucleotide repeat in intron 1. J Biol Chem.
274:13176–13180. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Buerger H, Gebhardt F, Schmidt H, et al:
Length and loss of heterozygosity of an intron 1 polymorphic
sequence of egfr is related to cytogenetic alterations and
epithelial growth factor receptor expression. Cancer Res.
60:854–857. 2000.
|
|
23
|
Tiseo M, Capelletti M, De Palma G, et al:
Epidermal growth factor receptor intron-1 polymorphism predicts
gefitinib outcome in advanced non-small cell lung cancer. J Thorac
Oncol. 3:1104–1111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tzeng CW, Frolov A, Frolova N, et al:
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1
polymorphism influences postoperative patient survival and in vitro
erlotinib response. Ann Surg Oncol. 14:2150–2158. 2007. View Article : Google Scholar
|
|
25
|
Etienne-Grimaldi MC, Pereira S, Magné N,
et al: Analysis of the dinucleotide repeat polymorphism in the
epidermal growth factor receptor (EGFR) gene in head and neck
cancer patients. Ann Oncol. 16:934–941. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brandt B, Meyer-Staeckling S, Schmidt H,
Agelopoulos K and Buerger H: Mechanisms of egfr gene transcription
modulation: relationship to cancer risk and therapy response. Clin
Cancer Res. 12:7252–7260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gebhardt F, Bürger H and Brandt B:
Modulation of EGFR gene transcription by a polymorphic repetitive
sequence - a link between genetics and epigenetics. Int J Biol
Markers. 15:105–110. 2000.PubMed/NCBI
|
|
28
|
Amador ML, Oppenheimer D, Perea S, et al:
An epidermal growth factor receptor intron 1 polymorphism mediates
response to epidermal growth factor receptor inhibitors. Cancer
Res. 64:9139–9143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JM, Yang SY, Yang PW, et al:
Polymorphism in epidermal growth factor receptor intron 1 predicts
prognosis of patients with esophageal cancer after chemoradiation
and surgery. Ann Surg Oncol. 18:2066–2073. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Upadhyay R, Jain M, Kumar S, Ghoshal UC
and Mittal B: Interaction of EGFR 497Arg>Lys with EGF +61A>G
polymorphism: modulation of risk in esophageal cancer. Oncol Res.
17:167–174. 2008.PubMed/NCBI
|
|
31
|
Jain M, Kumar S, Upadhyay R, Lal P, Tiwari
A, Ghoshal UC and Mittal B: Influence of apoptosis (BCL2, FAS),
cell cycle (CCND1) and growth factor (EGF, EGFR) genetic
polymorphisms on survival outcome: an exploratory study in squamous
cell esophageal cancer. Cancer Biol Ther. 6:1553–1558. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miller VA, Kris MG, Shah N, et al:
Bronchioloalveolar pathologic subtype and smoking history predict
sensitivity to gefitinib in advanced non-small-cell lung cancer. J
Clin Oncol. 22:1103–1109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kwak EL, Jankowski J, Thayer SP, et al:
Epidermal growth factor receptor kinase domain mutations in
esophageal and pancreatic adenocarcinomas. Clin Cancer Res.
12:4283–4287. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pühringer-Oppermann FA, Stein HJ and
Sarbia M: Lack of EGFR gene mutations in exons 19 and 21 in
esophageal (Barrett’s) adenocarcinomas. Dis Esophagus. 20:9–11.
2007.PubMed/NCBI
|
|
37
|
Sudo T, Mimori K, Nagahara H, et al:
Identification of EGFR mutations in esophageal cancer. Eur J Surg
Oncol. 33:44–48. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Janmaat ML, Gallegos-Ruiz MI, Rodriguez
JA, et al: Predictive factors for outcome in a phase II study of
gefitinib in second-line treatment of advanced esophageal cancer
patients. J Clin Oncol. 24:1612–1619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaneko K, Kumekawa Y, Makino R, et al:
EGFR gene alterations as a prognostic biomarker in advanced
esophageal squamous cell carcinoma. Front Biosci. 15:65–72. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thatcher N, Chang A, Parikh P, et al:
Gefitinib plus best supportive care in previously treated patients
with refractory advanced non-small-cell lung cancer: results from a
randomised, placebo-controlled, multicentre study (Iressa Survival
Evaluation in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar
|
|
41
|
Moore MJ, Goldstein D, Hamm J, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: a phase III trial of the
national cancer institute of Canada clinical trials group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
42
|
Hara F, Aoe M, Doihara H, et al: Antitumor
effect of gefitinib (‘Iressa’) on esophageal squamous cell
carcinoma cell lines in vitro and in vivo. Cancer Lett. 226:37–47.
2005.
|
|
43
|
Teraishi F, Kagawa S, Watanabe T, et al:
ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor
receptor-tyrosine kinase inhibitor, enhances the anti-cancer
effects of TRAIL in human esophageal squamous cell carcinoma. FEBS
Lett. 579:4069–4075. 2005.PubMed/NCBI
|
|
44
|
Taira N, Doihara H, Oota T, et al:
Gefitinib, an epidermal growth factor receptor blockade agent,
shows additional or synergistic effects on the radiosensitivity of
esophageal cancer cells in vitro. Acta Med Okayama. 60:25–34.
2006.
|
|
45
|
Ferry DR, Anderson M, Beddard K, et al: A
phase II study of gefitinib monotherapy in advanced esophageal
adenocarcinoma: evidence of gene expression, cellular, and clinical
response. Clin Cancer Res. 13:5869–5875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Javle M, Pande A, Iyer R, et al: Pilot
study of gefitinib, oxaliplatin, and radiotherapy for esophageal
adenocarcinoma: tissue effect predicts clinical response. Am J Clin
Oncol. 31:329–334. 2008. View Article : Google Scholar
|
|
47
|
Rodriguez CP, Adelstein DJ, Rice TW, et
al: A phase II study of perioperative concurrent chemotherapy,
gefitinib, and hyperfractionated radiation followed by maintenance
gefitinib in locoregionally advanced esophagus and gastroesophageal
junction cancer. J Thorac Oncol. 5:229–235. 2010. View Article : Google Scholar
|
|
48
|
Sunpaweravong P, Sunpaweravong S,
Sangthawan D, Puttawibul P and Mitarnun W: Combination of
gefitinib, cisplatin and 5-FU chemotherapy, and radiation therapy
(RT) in newly-diagnosed patients with esophageal carcinoma. J Clin
Oncol. 25:46052007.
|
|
49
|
Dobelbower MC, Russo SM, Raisch KP, et al:
Epidermal growth factor receptor tyrosine kinase inhibitor,
erlotinib, and concurrent 5-fluorouracil, cisplatin and
radiotherapy for patients with esophageal cancer: a phase I study.
Anticancer Drugs. 17:95–102. 2006. View Article : Google Scholar
|
|
50
|
Ilson DH, Kelsen D, Shah M, et al: A phase
2 trial of erlotinib in patients with previously treated squamous
cell and adenocarcinoma of the esophagus. Cancer. 117:1409–1414.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li G, Hu W, Wang J, et al: Phase II study
of concurrent chemoradiation in combination with erlotinib for
locally advanced esophageal carcinoma. Int J Radiat Oncol Biol
Phys. 78:1407–1412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ku GY and Ilson DH: Esophagogastric
cancer: targeted agents. Cancer Treat Rev. 36:235–248. 2010.
View Article : Google Scholar : PubMed/NCBI
|
